Clinical Trial Update: NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating NT-I7 in combination with atezolizumab for untreated PD-L1-expressing locally advanced or metastatic non-small cell lung cancer is acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• NT-I7

Snippet

Sponsor: NeoImmuneTech | Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING